Future investigations will be essential to clarify whether IL-6, IL-1β, and other pro-inflammatory cytokines produced during COVID-19 may affect tumor cells and the TME, possibly supporting the use of anti-cytokine therapies in cancer patients with COVID-19. The gene discussed is IL1B; the disease is COVID-19.